SITC 2021 | Targeting TREM-1 in solid tumors

Nadine Jahchan, BSc, PhD, Pionyr Immunotherapeutics, San Francisco, CA, discusses targeting triggering receptor expressed on myeloid cells 1 (TREM-1) in the tumor microenvironment. TREM-1 is highly expressed in immunosuppressive myeloid cells such as tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), and monocytic myeloid-derived suppressor cells (mMDSCs). By developing an anti-TREM-1 antibody, anti-tumor immunity can be achieved. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.